MedTrace Logo

Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2)

NCT03792321 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-01-04

No results posted yet for this study

Summary

Aim of the study was to investigate the effects of testosterone replacement therapy on components of metabolic syndrome, vascular function and morphology, grade of non-alcoholic fatty liver disease (NAFLD), bone mineral density (BMD) and health-related quality of life.

Conditions

  • Hypogonadism, Male
  • Diabetes Mellitus, Type 2
  • Obesity

Interventions

DRUG

Testosterone Undecanoate

1000 mg i.m. every 10 weeks

DRUG

Placebo

Sponsors & Collaborators

  • University Medical Centre Ljubljana

    lead OTHER

Principal Investigators

  • Kristina Groti Antonic, MD, PhD · University Medical Centre Ljubljana

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-10
Primary Completion
2015-03-05
Completion
2018-03-05

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03792321 on ClinicalTrials.gov